Most cited papers from London Cancer

London Cancer

What are the most cited papers from London Cancer?

The most cited paper from London Cancer is "Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing" (Marco Gerlinger et al., 2012), with 7,931 citations. Next come "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)" (6,023) and "Cancer statistics for the year 2020: An overview" (5,836).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 693 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Marco Gerlinger et al. · New England Journal of Medicine Open access	7 Mar 2012	7,931
2	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors	2 Jan 2016	6,023
3	Cancer statistics for the year 2020: An overview Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram et al. · International Journal of Cancer Open access	5 Apr 2021	5,836
4	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Juan W. Valle, Harpreet Singh Wasan, Daniel H. Palmer et al. · New England Journal of Medicine Open access	7 Apr 2010	4,489
5	The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature Open access1,384 authors	5 Feb 2020	3,854
6	Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature Open access1,324 authors	5 Feb 2020	3,360
7	DNA methylation-based classification of central nervous system tumours David Capper et al. · Nature Open access143 authors	13 Mar 2018	3,228
8	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future Nicholas McGranahan, Charles Swanton · Cell Open access	Feb 2017	3,002
9	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic Timothy An-thy Chan, Mark M. Yarchoan, Elizabeth M. Jaffee et al. · Annals of Oncology Open access	Nov 2018	2,932
10	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors	2 Jan 2021	2,743
11	Tracking the Evolution of Non–Small-Cell Lung Cancer Mariam Jamal‐Hanjani et al. · New England Journal of Medicine Open access	26 Apr 2017	2,501
12	Artificial intelligence in cancer imaging: Clinical challenges and applications Wenya Linda Bi, Ahmed Hosny, Matthew B. Schabath et al. · CA A Cancer Journal for Clinicians Open access	5 Feb 2019	1,886
13	Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B Amit C. Nathwani et al. · New England Journal of Medicine Open access	10 Dec 2011	1,875
14	Introduction to Radiomics Marius Erik Mayerhoefer, Andrzej Materka, Georg Langs et al. · Journal of Nuclear Medicine Open access	14 Feb 2020	1,803
15	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert Louis Coleman et al. · The Lancet Open access117 authors	12 Sep 2017	1,729
16	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma John A. Bridgewater, Peter R. Galle, Shahid Ahmed Khan et al. · Journal of Hepatology Open access	27 Mar 2014	1,570
17	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu et al. · Annals of Oncology Open access159 authors	30 Mar 2020	1,567
18	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer Scott Kopetz et al. · New England Journal of Medicine Open access	30 Sep 2019	1,500
19	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma Tyler R. Simpson, Fubin Li, Welby Montalvo-Ortiz et al. · The Journal of Experimental Medicine Open access	29 Jul 2013	1,498
20	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Nicholas McGranahan et al. · Cell Open access223 authors	26 Oct 2017	1,361
21	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B Amit Chunilal Nathwani et al. · New England Journal of Medicine Open access	20 Nov 2014	1,276
22	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing Marco Gerlinger et al. · Nature Genetics Open access	2 Feb 2014	1,271
23	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Elizabeth M. Swisher et al. · The Lancet Oncology Open access	28 Nov 2016	1,218
24	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Matthew David Hellmann et al. · Cancer Cell Open access	12 Apr 2018	1,197
25	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution Elza C. de Bruin et al. · Science Open access	9 Oct 2014	1,176
26	The evolutionary history of 2,658 cancers Moritz Gerstung et al. · Nature Open access1,441 authors	5 Feb 2020	1,149
27	Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity Santiago Zelenay, Annemarthe G. van der Veen, Jan P. Böttcher et al. · Cell Open access	Sep 2015	1,142
28	Role of the Immune system in chronic pain Fabien Marchand, Mauro Perretti, Stephen Brendan McMahon · Nature reviews. Neuroscience Review	Jul 2005	1,101
29	Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma Jan C. Buckner et al. · New England Journal of Medicine Open access	6 Apr 2016	1,071
30	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma Josep Maria Llovet, Thierry de Baère, Laura Kulik et al. · Nature Reviews Gastroenterology & Hepatology Review	28 Jan 2021	1,068
31	From tokenism to empowerment: progressing patient and public involvement in healthcare improvement Josephine Enyonam Ocloo, Rachel Matthews · BMJ Quality & Safety Open access	18 Mar 2016	1,031
32	Cancer heterogeneity: implications for targeted therapeutics Rosalie Anne Fisher, Lajos Pusztai, Charles Swanton · British Journal of Cancer Open access	8 Jan 2013	1,016
33	Neoantigen-directed immune escape in lung cancer evolution Rachel Rosenthal et al. · Nature Open access	Mar 2019	1,006
34	Patterns of somatic structural variation in human cancer genomes Yilong Li et al. · Nature Open access1,411 authors	5 Feb 2020	1,005
35	Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Sibylle Loibl et al. · Annals of Oncology Open access	13 Dec 2023	991
36	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI Justin E. Davies et al. · New England Journal of Medicine Open access	18 Mar 2017	982
37	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Tim Maughan et al. · The Lancet Open access	Jun 2011	969
38	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis Samra Turajlic, Kevin Litchfield, Hang Xu et al. · The Lancet Oncology Open access	7 Jul 2017	953
39	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition Kevin Litchfield et al. · Cell ReviewOpen access	27 Jan 2021	918
40	Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Waseem Qasim et al. · Science Translational Medicine Open access	25 Jan 2017	909
41	EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent Kexin Xu et al. · Science Open access	13 Dec 2012	895
42	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal Samra Turajlic et al. · Cell Open access	Apr 2018	892
43	Multiple myeloma Niels W.C.J. van de Donk, Charlotte Pawlyn, Kwee Yong · The Lancet	2021	891
44	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone Sam Behjati et al. · Nature Genetics Open access	27 Oct 2013	872
45	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · JAMA Oncology Open access	17 Aug 2017	850
46	Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Jesús F. San Miguel et al. · New England Journal of Medicine Open access	5 Jun 2023	814
47	Genetic variegation of clonal architecture and propagating cells in leukaemia Kristina Anderson, Christoph Lutz, Frederik W. van Delft et al. · Nature	15 Dec 2010	813
48	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Robert E Marcus, Andrew John Davies, Kiyoshi Ando et al. · New England Journal of Medicine Open access	4 Oct 2017	812
49	Lung adenocarcinoma promotion by air pollutants William D. Hill et al. · Nature Open access326 authors	5 Apr 2023	809
50	Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Isidro Cortés-Ciriano et al. · Nature Genetics Open access1,407 authors	5 Feb 2020	793

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.